KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
10.03
-0.61 (-5.73%)
At close: Feb 21, 2025, 4:00 PM
9.90
-0.13 (-1.30%)
After-hours: Feb 21, 2025, 7:44 PM EST
KalVista Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for KalVista Pharmaceuticals stock have an average target of 25.67, with a low estimate of 19 and a high estimate of 35. The average target predicts an increase of 155.93% from the current stock price of 10.03.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KalVista Pharmaceuticals stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 5 | 5 |
| Buy | 1 | 1 | 1 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 6 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Initiates $19 | Buy | Initiates | $19 | +89.43% | Jan 31, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +199.10% | Jan 7, 2025 |
| B of A Securities | B of A Securities | Strong Buy Initiates $22 | Strong Buy | Initiates | $22 | +119.34% | Dec 18, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Dec 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +99.40% | Dec 6, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
46.86M
EPS This Year
-3.72
from -3.44
EPS Next Year
-2.84
from -3.72
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 89.5M | 202.2M | ||
| Avg | n/a | 46.9M | 151.6M | ||
| Low | n/a | 17.8M | 108.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 331.6% | ||
| Avg | - | - | 223.5% | ||
| Low | - | - | 131.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.57 | -1.92 | -0.02 | ||
| Avg | -3.72 | -2.84 | -1.22 | ||
| Low | -3.96 | -3.68 | -2.16 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.